Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models
The Bcr-Abl oncogene causes human Philadelphia chromosome-positive (Ph + ) leukemias, including B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML) with chronic phase (CML-CP) to blast crisis (CML-BC). Previous studies have demonstrated that Src family kinases are required...
Gespeichert in:
Veröffentlicht in: | International journal of hematology 2012-02, Vol.95 (2), p.167-175 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The Bcr-Abl oncogene causes human Philadelphia chromosome-positive (Ph
+
) leukemias, including B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML) with chronic phase (CML-CP) to blast crisis (CML-BC). Previous studies have demonstrated that Src family kinases are required for the induction of B-ALL, but not for CML, which is induced by Bcr-Abl in mice. In contrast, it has been reported that Fyn is up-regulated in human CML-BC compared with CML-CP, implicating Fyn in the blast crisis transition. Here, we aimed to delineate the exact role of Fyn in the induction/progression of Ph
+
leukemias. We found that Fyn is expressed in mouse hematopoietic cells at varying stages of development, including c-kit
+
Sca-1
+
Lin
−
cells. Notably, Fyn is highly expressed in some of human lymphomas, but not in human Ph
+
leukemias including CML-BC. In mouse bone marrow transplantation models, mice transplanted with wild-type or Fyn-deficient bone marrow cells transduced with Bcr-Abl showed no differences in the development of B-ALL or CML-like diseases. Similarly, Fyn deficiency failed to impact the development of myeloid CML-BC induced by Bcr-Abl and Hes1. Elevated expression of Fyn was not found in mouse samples of Bcr-Abl-mediated CML- and CML-BC-like diseases. Thus, Fyn is not required for the pathogenesis of Bcr-Abl-mediated leukemias. |
---|---|
ISSN: | 0925-5710 1865-3774 |
DOI: | 10.1007/s12185-011-0994-5 |